Enhancement of the liver and pancreas in the hepatic arterial dominant phase: Comparison of hepatocyte-specific MRI contrast agents, gadoxetic acid and gadobenate dimeglumine, on 3 and 1.5 Tesla MRI in the same patient

Journal of Magnetic Resonance Imaging

Volumn 37, Issue 4, 2013, Pages 903-908

  Kim, Hee Jin ^a,b   Kim, Bong Soo ^a   Kim, Mi Jeong ^a   Kim, Seong Hyun ^a   De Campos, Rafael O P ^a   Hernandes, Mateus ^a   Semelka, Richard C ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b Eulji University   (South Korea)

Author keywords

abdominal imaging; contrast media; gadobenate dimeglumine; gadolinium; gadoxetic acid; magnetic resonance imaging

Indexed keywords

GADOBENATE DIMEGLUMINE; GADOXETIC ACID;

ARTICLE; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIGESTIVE TRACT PARAMETERS; HEPATIC ARTERIAL DOMINANT PHASE; HUMAN; LIVER; LIVER CELL; MAGNETIC FIELD; NODULAR HYPERPLASIA; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PANCREAS; PRIORITY JOURNAL;

ADENOMA, LIVER CELL; ADULT; CARCINOMA, HEPATOCELLULAR; CONTRAST MEDIA; FEMALE; FOCAL NODULAR HYPERPLASIA; GADOLINIUM DTPA; HEMANGIOMA; HEPATIC ARTERY; HEPATOCYTES; HUMANS; IMAGE ENHANCEMENT; IMAGE INTERPRETATION, COMPUTER-ASSISTED; LIVER; LIVER CIRRHOSIS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MAGNETIC RESONANCE IMAGING; MALE; MASS SCREENING; MEGLUMINE; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; PANCREAS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY;

EID: 84875467588     PISSN: 10531807     EISSN: 15222586     Source Type: Journal    
DOI: 10.1002/jmri.23874     Document Type: Article

References (35)

1. Semelka RC, Martin DR, Balci NC,. Magnetic resonance imaging of the liver: how I do it. J Gastroenterol Hepatol 2006; 21: 632-637.
2. Martin DR, Semelka RC,. Magnetic resonance imaging of the liver: review of techniques and approach to common diseases. Semin Ultrasound CT MR 2005; 26: 116-131. (Pubitemid 40780949)
3. Balci NC, Semelka RC,. Contrast agents for MR imaging of the liver. Radiol Clin North Am 2005; 43: 887-898, viii. (Pubitemid 41138194)
4. Semelka RC, Helmberger TK,. Contrast agents for MR imaging of the liver. Radiology 2001; 218: 27-38.
5. Schneider G, Reimer P, Mamann A, Kirchin MA, Morana G, Grazioli L,. Contrast agents in abdominal imaging: current and future directions. Top Magn Reson Imaging 2005; 16: 107-124. (Pubitemid 43186781)
6. Goncalves Neto JA, Altun E, Elazzazi M, Vaidean GD, Chaney M, Semelka RC,. Enhancement of abdominal organs on hepatic arterial phase: quantitative comparison between 1.5- and 3.0-T magnetic resonance imaging. Mag Reson Imaging 2010; 28: 47-55.
7. Goncalves Neto JA, Altun E, Vaidean G, et al. Early contrast enhancement of the liver: exact description of subphases using MRI. Magn Reson Imaging 2009; 27: 792-800.
8. Okada M, Imai Y, Kim T, et al. Comparison of enhancement patterns of histologically confirmed hepatocellular carcinoma between gadoxetate- and ferucarbotran-enhanced magnetic resonance imaging. J Magn Reson Imaging 2010; 32: 903-913.
9. Hammerstingl R, Adam G, Ayuso JR, et al. Comparison of 1.0 M gadobutrol and 0.5 M gadopentetate dimeglumine-enhanced magnetic resonance imaging in five hundred seventy-two patients with known or suspected liver lesions: results of a multicenter, double-blind, interindividual, randomized clinical phase-III trial. Invest Radiol 2009; 44: 168-176.
10. Kim HJ, Kim KW, Byun JH, et al. Comparison of mangafodipir trisodium- and ferucarbotran-enhanced MRI for detection and characterization of hepatic metastases in colorectal cancer patients. AJR Am J Roentgenol 2006; 186: 1059-1066.
11. Simon G, Link TM, Wortler K, et al. Detection of hepatocellular carcinoma: comparison of Gd-DTPA- and ferumoxides-enhanced MR imaging. Eur Radiol 2005; 15: 895-903. (Pubitemid 41166721)
12. Maravilla KR, Maldjian JA, Schmalfuss IM, et al. Contrast enhancement of central nervous system lesions: multicenter intraindividual crossover comparative study of two MR contrast agents. Radiology 2006; 240: 389-400. (Pubitemid 44098634)
13. Huppertz A, Haraida S, Kraus A, et al. Enhancement of focal liver lesions at gadoxetic acid-enhanced MR imaging: correlation with histopathologic findings and spiral CT-initial observations. Radiology 2005; 234: 468-478. (Pubitemid 40139918)
14. Huppertz A, Balzer T, Blakeborough A, et al. Improved detection of focal liver lesions at MR imaging: multicenter comparison of gadoxetic acid-enhanced MR images with intraoperative findings. Radiology 2004; 230: 266-275. (Pubitemid 37549812)
15. Hammerstingl R, Huppertz A, Breuer J, et al. Diagnostic efficacy of gadoxetic acid (Primovist)-enhanced MRI and spiral CT for a therapeutic strategy: comparison with intraoperative and histopathologic findings in focal liver lesions. Eur Radiol 2008; 18: 457-467. (Pubitemid 351248177)
16. Pintaske J, Martirosian P, Graf H, et al. Relaxivity of Gadopentetate Dimeglumine (Magnevist), Gadobutrol (Gadovist), and Gadobenate Dimeglumine (MultiHance) in human blood plasma at 0.2, 1.5, and 3 Tesla. Invest Radiol 2006; 41: 213-221. (Pubitemid 44406181)
17. Rohrer M, Bauer H, Mintorovitch J, Requardt M, Weinmann HJ,. Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths. Invest Radiol 2005; 40: 715-724. (Pubitemid 41546838)
18. Feuerlein S, Gupta RT, Boll DT, Merkle EM,. Hepatocellular MR contrast agents: enhancement characteristics of liver parenchyma and portal vein after administration of gadoxetic acid in comparison to gadobenate dimeglumine. Eur J Radiol 2012; 81: 2037-2041.
19. Sharma P, Kitajima HD, Kalb B, Martin DR,. Gadolinium-enhanced imaging of liver tumors and manifestations of hepatitis: pharmacodynamic and technical considerations. Top Magn Reson Imaging 2009; 20: 71-78.
20. Grazioli L, Bondioni MP, Haradome H, et al. Hepatocellular adenoma and focal nodular hyperplasia: value of gadoxetic acid-enhanced MR imaging in differential diagnosis. Radiology 2012; 262: 520-529.
21. Grazioli L, Morana G, Kirchin MA, Schneider G,. Accurate differentiation of focal nodular hyperplasia from hepatic adenoma at gadobenate dimeglumine-enhanced MR imaging: prospective study. Radiology 2005; 236: 166-177. (Pubitemid 40853309)
22. Grazioli L, Morana G, Federle MP, et al. Focal nodular hyperplasia: morphologic and functional information from MR imaging with gadobenate dimeglumine. Radiology 2001; 221: 731-739. (Pubitemid 33101765)
23. Seale MK, Catalano OA, Saini S, Hahn PF, Sahani DV,. Hepatobiliary- specific MR contrast agents: role in imaging the liver and biliary tree. Radiographics 2009; 29: 1725-1748.
24. Kuwatsuru R, Kadoya M, Ohtomo K, et al. Comparison of gadobenate dimeglumine with gadopentetate dimeglumine for magnetic resonance imaging of liver tumors. Invest Radiol 2001; 36: 632-641. (Pubitemid 33021091)
25. Schneider G, Maas R, Schultze Kool L, et al. Low-dose gadobenate dimeglumine versus standard dose gadopentetate dimeglumine for contrast-enhanced magnetic resonance imaging of the liver: an intra-individual crossover comparison. Invest Radiol 2003; 38: 85-94. (Pubitemid 36125892)
26. Nural MS, Gokce E, Danaci M, Bayrak IK, Diren HB,. Focal liver lesions: whether a standard dose (0.05 mmol/kg) gadobenate dimeglumine can provide the same diagnostic data as the 0.1 mmol/kg dose. Eur J Radiol 2008; 66: 65-74. (Pubitemid 351434515)
27. de Haen C, Gozzini L,. Soluble-type hepatobiliary contrast agents for MR imaging. J Magn Reson Imaging 1993; 3: 179-186.
28. Zizka J, Klzo L, Ferda J, Mrklovsky M, Bukac J,. Dynamic and delayed contrast enhancement in upper abdominal MRI studies: comparison of gadoxetic acid and gadobutrol. Eur J Radiol 2007; 62: 186-191. (Pubitemid 46560352)
29. Reimer P, Rummeny EJ, Shamsi K, et al. Phase II clinical evaluation of Gd-EOB-DTPA: dose, safety aspects, and pulse sequence. Radiology 1996; 199: 177-183. (Pubitemid 26098637)
30. Ringe KI, Husarik DB, Sirlin CB, Merkle EM,. Gadoxetate disodium-enhanced MRI of the liver: part 1, protocol optimization and lesion appearance in the noncirrhotic liver. AJR Am J Roentgenol 2010; 195: 13-28.
31. Cruite I, Schroeder M, Merkle EM, Sirlin CB,. Gadoxetate disodium-enhanced MRI of the liver: part 2, protocol optimization and lesion appearance in the cirrhotic liver. AJR Am J Roentgenol 2010; 195: 29-41.
32. Shellock FG, Parker JR, Pirovano G, et al. Safety characteristics of gadobenate dimeglumine: clinical experience from intra- and interindividual comparison studies with gadopentetate dimeglumine. J Magn Reson Imaging 2006; 24: 1378-1385. (Pubitemid 44871885)
33. Thomsen HS,. How to avoid nephrogenic systemic fibrosis: current guidelines in Europe and the United States. Radiol Clin North Am 2009; 47: 871-875, vii.
34. Kanal E, Barkovich AJ, Bell C, et al. ACR guidance document for safe MR practices: 2007. AJR Am J Roentgenol 2007; 188: 1447-1474. (Pubitemid 46866845)
35. Shellock FG, Parker JR, Venetianer C, Pirovano G, Spinazzi A,. Safety of gadobenate dimeglumine (MultiHance): summary of findings from clinical studies and postmarketing surveillance. Invest Radiol 2006; 41: 500-509. (Pubitemid 44284184)